RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+88.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.13B
AUM Growth
+$5.13B
(+62%)
Cap. Flow
+$1.15B
Cap. Flow
% of AUM
22.34%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
66
New
18
Increased
9
Reduced
12
Closed
9
Top Buys
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$419M |
| 2 |
Novavax
NVAX
|
$397M |
| 3 |
Vaxcyte
PCVX
|
$174M |
| 4 |
MacroGenics
MGNX
|
$128M |
| 5 |
Legend Biotech
LEGN
|
$106M |
Top Sells
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$233M |
| 2 |
Exelixis
EXEL
|
$77.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$43.2M |
| 4 |
Gilead Sciences
GILD
|
$41M |
| 5 |
Relmada Therapeutics
RLMD
|
$23.6M |
Sector Composition
| 1 | Healthcare | 93.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARYBU
51
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
| $8.12M | 0.16% |
+700,000
| New | +$8.12M |
|
|
GRTX
52
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $5.89M | 0.11% |
825,118
-67,997
| -8% | -$485K |
|
53
ESSA Pharma
EPIX
$11.2M
| $5.27M | 0.1% |
849,300
-110,000
| -11% | -$682K |
|
54
X4 Pharmaceuticals
XFOR
$70M
| $5.21M | 0.1% |
559,494
-42,780
| -7% | -$399K |
|
55
Insmed
INSM
$30.3B
| $2.41M | 0.05% |
87,405
| – | – |
|
56
Ovid Therapeutics
OVID
$94.6M
| $2.1M | 0.04% |
+285,000
| New | +$2.1M |
|
57
Cartesian Therapeutics
RNAC
$267M
| $270K | 0.01% |
95,000
-775,633
| -89% | -$2.2M |
|
|
RARX
58
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| – | – |
-4,858,260
| Closed | -$233M |
|
|
PTLA
59
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-429,399
| Closed | -$3.06M |
|
|
IMGN
60
DELISTED
Immunogen Inc
IMGN
| – | – |
-5,166,303
| Closed | -$17.6M |
|
61
Vericel Corp
VCEL
$1.69B
| – | – |
-100,000
| Closed | -$917K |
|
62
uniQure
QURE
$954M
| – | – |
-82,180
| Closed | -$3.9M |
|
63
NovoCure
NVCR
$1.35B
| – | – |
-259,099
| Closed | -$17.4M |
|
|
64
Gilead Sciences
GILD
$140B
| – | – |
-548,000
| Closed | -$41M |
|
|
65
Exelixis
EXEL
$9.95B
| – | – |
-4,524,961
| Closed | -$77.9M |
|
66
Compugen
CGEN
$133M
| – | – |
-2,957,434
| Closed | -$21.5M |
|